Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at $25,742,347.58. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

William Lewis also recently made the following trade(s):

• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.79, for a total value of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $81.03, for a total value of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total value of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The shares were sold at an average price of $66.02, for a total value of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Trading Up 2.5 %

Insmed stock opened at $78.94 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The stock has a market capitalization of $14.29 billion, a PE ratio of -14.12 and a beta of 1.28. The business’s fifty day moving average is $76.88 and its 200 day moving average is $73.74.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System boosted its position in Insmed by 4.5% in the fourth quarter. California State Teachers Retirement System now owns 153,343 shares of the biopharmaceutical company’s stock worth $10,587,000 after purchasing an additional 6,601 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Insmed by 10.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 307 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Insmed in the fourth quarter worth about $6,798,000. Mackenzie Financial Corp raised its stake in shares of Insmed by 12.5% in the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 1,213 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Insmed in the fourth quarter worth about $259,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on INSM shares. Wells Fargo & Company upped their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Stifel Nicolaus cut their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. Guggenheim reiterated a “buy” rating and issued a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $100.00 target price on shares of Insmed in a report on Wednesday. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.